Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Catalyst Pharmaceuticals (CPRX) over the last 14 years, with Q3 2025 value amounting to $161000.0.

  • Catalyst Pharmaceuticals' Other Non-Current Liabilities fell 9421.9% to $161000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $161000.0, marking a year-over-year decrease of 9421.9%. This contributed to the annual value of $315000.0 for FY2024, which is 8943.66% down from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Other Non-Current Liabilities is $161000.0, which was down 9421.9% from $309000.0 recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $14.7 million for Q3 2022, and its period low was $161000.0 during Q3 2025.
  • Its 4-year average for Other Non-Current Liabilities is $5.4 million, with a median of $2.8 million in 2024.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Other Non-Current Liabilities tumbled by 2209.79% in 2024 and then crashed by 9421.9% in 2025.
  • Catalyst Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $14.1 million in 2022, then crashed by 78.8% to $3.0 million in 2023, then tumbled by 89.44% to $315000.0 in 2024, then crashed by 48.89% to $161000.0 in 2025.
  • Its last three reported values are $161000.0 in Q3 2025, $309000.0 for Q2 2025, and $259000.0 during Q1 2025.